SCHEMBL3302852

SCHEMBL3302852

Nc1nc(OCc2ccc(Cl)cc2)c2[nH]cnc2n1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 9/20 0.76
CDK1 P06493 10/20 0.76
CCNB1 P14635 10/20 0.76
CCNA2 P20248 10/20 0.76
CDK2 P24941 10/20 0.76
CCNA1 P78396 10/20 0.76
MGMT P16455 8/20 0.76
LMNA P02545 1/20 0.76
CYP1A2 P05177 1/20 0.76
CYP3A4 P08684 1/20 0.76
CYP2D6 P10635 1/20 0.76
CYP2C9 P11712 1/20 0.76
TSHR P16473 1/20 0.76
NFKB1 P19838 1/20 0.76
CYP2C19 P33261 1/20 0.76
BLM P54132 1/20 0.76
PMP22 Q01453 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29749175 0.88 MGMT (0.81) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL23124359 0.88 MGMT (0.81) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL3302326 0.86 PIN1 (1.00) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL3338895 0.86 PIN1 (0.76) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL3297931 0.86 PIN1 (1.00) PIN1CDK1CCNB1CCNA2CDK2
6-O-Benzylguanine SCHEMBL61740 0.86 PIN1 (1.00) PIN1CDK1CCNB1CCNA2CDK2
6-O-Benzylguanine SCHEMBL31517079 0.86 PIN1 (1.00) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL3305085 0.86 PIN1 (0.75) PIN1CDK1CCNB1CCNA2CDK2
6-O-Benzylguanine SCHEMBL4631744 0.85 PIN1 (0.97) PIN1CDK1CCNB1CCNA2CDK2
SCHEMBL3305088 0.82 PIN1 (0.73) PIN1CDK1CCNB1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008109417-A1 MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2008-09-12 WO claimed
US-20140296264-A1 MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS CASE WESTERN RESERVE UNIVERSITY 2014-10-02 US disclosed
US-8791081-B2 MGMT inhibitor combination for the treatment of neoplastic disorders CASE WESTERN RESERVE UNIVERSITY (US) 2014-07-29 US disclosed
US-20100093647-A1 MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS LIU LILI 2010-04-15 US disclosed
WO-2008109417-A1 MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093647-A1 MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS MGMT, MSH2, UNG PIN1 2059/4885CDK1 566/4885CCNB1 569/4885
US-20140296264-A1 MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS MGMT, MSH2, UNG PIN1 1953/4885CDK1 566/4885CCNB1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.